

# ANNUAL REPORT

2024



**Shifa**  
International  
Hospitals Ltd.



SHIFA CLINICAL RESEARCH CENTER

# ANNUAL REPORT

2  
0  
2  
4

“ RESEARCH IS TO SEE WHAT EVERYBODY ELSE HAS SEEN, AND TO THINK WHAT NOBODY ELSE HAS THOUGHT. ”

*Albert Szent-Györgyi*



DR. SABAHAH TAHIR  
EDITOR



DR. QASIM MEHMOOD  
CO-EDITOR

# TABLE OF CONTENTS

Vision & Mission.....	01
CEO's Message .....	02
CMO's Message .....	03
COO's Message .....	04
Director's Message.....	05
Associate Director's Message.....	06
Meet the SCRC team.....	07
SCRC Policies 2024.....	08
Meeting Calendar 2024.....	09
The Clinical Trial Process.....	10
Clinical Trials at SCRC over the years.....	11
Clinical Trials in 2024.....	12
Upcoming Trials.....	14
Investigator-Initiated Protocols at SIH in 2024	15
Shifa Cancer Registry.....	16
Statistical Facilitation.....	17
Capacity Building.....	17
Publication Trend Over the Years .....	18
Feasibility Studies.....	18
SCRC Publications .....	19
Highlights of the Year.....	21

# OUR VISION

To be a regional leader in innovative and groundbreaking clinical research, to advance medical knowledge (“Illaman Nafian”), and to improve the well-being of the community at large by fostering collaboration among researchers, clinicians, and industry partners.

# OUR MISSION

To provide an unparalleled platform in the region, uniquely positioned to lead impactful, and ethical clinical research that transforms clinical practice on a global scale.

# CEO's MESSAGE

As Shifa Clinical Research Center presents this year's annual report, I am reminded of the profound words from the Holy Quran:

"... And He gave you hearing, sight, and intellect that you might give thanks" (Quran 16:78). This divine exhortation to reflect and acquire knowledge underscores our shared responsibility to pursue wisdom and understanding for the benefit of humanity.



Our clinical research center embodies this timeless principle. Research is not merely an adjunct to healthcare; it is its very foundation. Through exploration and discovery, we transform challenges into opportunities, charting a course for improved patient care and groundbreaking innovations.

This year, like the previous ones, has also been marked by remarkable achievements at SCRC – advancing clinical trials, fostering collaborations, and refining methodologies—all driven by a commitment to excellence. These efforts have brought us closer to our ultimate goal. That is none other than improving lives. The dedication of our researchers, clinicians, and staff exemplifies the spirit of inquiry that Islam so profoundly emphasizes.

Throughout history, healthcare has always functioned at the crossroads of tradition and transformation. Modern medicine draws from centuries of accumulated knowledge while embracing the unprecedented opportunities presented by technology and data. In this dynamic landscape, our research center has not only risen to the challenge but has also set new benchmarks for excellence.

As stewards of this noble mission, we are reminded of the Quranic call to constantly seek knowledge: "Say, 'Are those who know equal to those who do not know?'" (Quran 39:9). Let us honor this calling by continuing to ask questions, challenge norms, and innovate relentlessly.

With thanks and admiration for our teams and unwavering optimism for the future, I second this SCRC invitation to you to explore the highlights of our year and join us in envisioning an even brighter tomorrow.

Dr. Zeeshan Bin Ishtiaque  
Chief Executive Officer

# CMO's MESSAGE



As the Chief Medical Officer of Shifa International Hospitals, it is both an honor and a privilege to reflect on our continued commitment to advancing medical research and clinical excellence. Over the past year, our team has worked tirelessly to improve patient care through cutting-edge research.

At Shifa, we are deeply committed to delivering exceptional, evidence-based clinical trials that lead to meaningful healthcare breakthroughs. Our organizational ethos revolves around quality, integrity, and the pursuit of excellence in every project we undertake. This commitment not only drives the research initiatives we sponsor but also shapes our approach to patient safety, ethical practices, and the rigorous standards we uphold in every phase of the research process. Our dedicated team of researchers, clinicians, and support staff work collaboratively to design and conduct trials that provide crucial insights into medical conditions and treatments. This ongoing dedication ensures that we remain at the forefront of scientific discovery, contributing to global health advancements, and directly benefiting the communities we serve.

Looking forward, Shifa Clinical Research Centre will continue to strengthen its position as a leader in clinical research. We will expand our efforts in innovative research methodologies, enhance our partnerships with leading academic and pharmaceutical institutions, and maintain our focus on the highest ethical standards and scientific rigor.

Dr. Khawaja Junaid Mustafa  
Chief Medical Officer (CMO)

# COO's MESSAGE



As we reflect on the milestones of the previous year, one theme emerges as central to our success: the symbiotic relationship between research and clinical operations. There is no concept of research in isolation; it helps drive the quality, efficiency, and impact of every aspect of patient care.

In a world where healthcare faces ever-growing complexities, Shifa Clinical Research Center has embraced research as the cornerstone of operational excellence. We have demonstrated how research-driven insights lead to actionable solutions—improving processes, elevating patient outcomes, and setting new standards for clinical excellence.

Thankfully, our dedicated teams are working hard to integrate research with day-to-day operations, ensuring that every discovery is translated into practical benefits. From refining treatment protocols to leveraging data analytics for predictive care, we are making strides toward a future where healthcare is not only responsive but also proactive. What sets SCRC apart is our unwavering commitment to collaboration. By fostering partnerships across disciplines and institutions, we have created a fertile ground for innovation. These collaborations ensure that our work remains relevant and impactful, addressing real-world challenges with evidence-based solutions.

The journey we are on is as much about process improvement as it is about vision. Clinical research, when seamlessly integrated into operations, becomes the catalyst for sustainable growth, patient satisfaction, and systemic advancement.

I am confident that our combined efforts will continue to yield transformative results. The dedication of our researchers, clinicians, and support staff inspires me daily, reminding us that the pursuit of knowledge is, in itself, an act of service.

Thank you for your contributions to this mission. Together, we are creating a legacy of excellence that will shape healthcare for generations to come.

Taimoor Shah  
Chief Operating Officer

# DIRECTOR'S MESSAGE



It gives me a sense of immense pride when I reflect on the accomplishments of the Shifa Clinical Research Centre over the past year. Together, we have made significant progress in advancing clinical research, driving innovation, and fostering meaningful collaborations. These achievements are a testament to the unwavering commitment, expertise, and shared vision of our team, whose dedication continues to inspire excellence.

As we embrace the opportunities of a rapidly evolving healthcare landscape, we remain steadfast in our mission to leverage innovative methodologies, including AI-driven solutions, to enhance the efficiency and impact of clinical research. Our collective efforts are guided by a commitment to precision, integrity, and patient-centered care, ensuring meaningful contributions to the advancement of global health.

Looking to the future, we are energized by the possibilities ahead and remain united in our pursuit of groundbreaking discoveries. Thank you for being an integral part of this journey as we continue to strive for excellence and impact lives through research.

Prof. Dr. Maimoona Siddiqui  
Director Shifa Clinical Research  
Center & Medical Education

# ASSOCIATE DIRECTOR'S MESSAGE

As we close 2024, I'm pleased to share the significant progress and achievements of the Shifa Clinical Research Center (SCRC). Our team's dedication and expertise have earned international recognition, establishing Shifa International Hospital as a leading institution in Pakistan's research landscape. Notable achievements include achieving third and fourth rankings in recruitment for the HIPATTACK-2 and ASPIRE-AF trials, respectively.



Operationally, we've optimized our workflows and processes, boosting operational efficiency. Additionally, digitizing study documents has improved accessibility and efficiency. As we look to the future, we're eager to leverage our momentum and pursue growth and innovation opportunities. Key objectives include strengthening collaborations with Shifa researchers, CROs, and academic institutions, enhancing our infrastructure, and becoming a first-tier site for upcoming clinical studies in Pakistan.

I would like to express my heartfelt gratitude to our exceptional team members, stakeholders, and collaborators for their invaluable contributions to our success. Thank you for your ongoing support as we strive for even greater achievements.

Dr. Gul Nowshad  
Associate Director  
Shifa Clinical Research Center,

# MEET THE SCRC TEAM



Mehwish Rafique

Biostatistics Lead



Nimra Altaf

Data Manager



Dr. Tehreem Zahid

Sr. Clinical Research Associate



Dr. Sundus Dadan

Sr. Clinical Research Associate



Raja Waseem

Sr. Research & Regulatory Pharmacist



Sumaira Gulzar

Senior Data Abstractor



Maliha Aziz

Biostatistician



Dr. Sofia Khan

Clinical Research Associate



Dr. Qasim Mehmood

Clinical Research Associate



Abdul Mannan Kiani

Research Coordinator



Muhammad Irfan

Office Assistant

# SCRC POLICIES

## RESEARCH OPERATIONS AND MANAGEMENT

- Policy for handling and storage of investigational products
- Policy for disbursement of trial funds at SCRC
- Indemnity insurance in clinical trials Shifa Clinical Research Center (SCRC)
- Policy for feasibility studies
- Policy for SCRC and MSA staff involvement in clinical research as contributors
- Policy for archiving clinical trials records
- Policy for destruction of research laboratory kits

## GOVERNANCE AND COMPLIANCE

- Policy for financial management of Shifa
- Policy for clinical trials appraisal committee
- Policy for accountability of sponsors / CROs of research
- Plagiarism policy
- Policy for laws, regulations, and hospital leadership in human subjects research
- Policy to oversee and review human subjects research
- Policy for eligibility and selection of principal investigator

**A Framework of Integrity: Core Policies Shaping Our Research**


## PATIENT AND SUBJECT WELFARE

- Policy for information to patients about their protection as research subjects
- Policy for information to patients and families about how to gain access to research
- Policy for informed consent in research
- Policy for staff/employees as research subjects in clinical research
- Policy for entry and/or transfer criteria for patient admission to specialized ward due to research
- Policy for intensive care admission of research subject
- Policy for adverse event reporting for clinical research

## DATA AND MONITORING


- Policy for travel grants
- Policy on research sponsorship PGME/SCRC
- Conflict of interest policy for clinical research
- Policy and procedure manual of cancer registry
- Shifa data and safety monitoring board policy
- Memorandum of understanding (MOU) policy for research with other institutions
- Policy for source documentation for clinical trials
- Policy for data sharing of research projects

# MEETING CALENDAR 2024



## SHIFA DATA SAFETY AND MONITORING BOARD

A quarterly independent data monitoring committee ensures protocol adherence and participant safety in human research



## CLINICAL TRIALS APPRAISAL COMMITTEE

A committee of administrative heads meets monthly or bimonthly to vet clinical trials' logistical, administrative, and financial viability



## INSTITUTIONAL REVIEW BOARD AND ETHICS COMMITTEE


The IRB and Ethics Committee meet monthly to review research protocols, ensuring they adhere to ethical standards and protocol requirements

# THE CLINICAL TRIAL PROCESS



# CLINICAL TRIALS AT SCRC

*Over the years*



TRIALS  
20+ Trials



PARTICIPANTS  
10,000+ Participants

# CLINICAL TRIALS IN 2024

TRIALS	PRINCIPAL INVESTIGATORS	SPONSORS	TOTAL RECRUITEMENT
<b>TRIALS IN ACTIVE PHASE</b>			
<p><b>HIP- ATTACK 2</b></p> <p>A multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization.</p>	 <p>Dr. Amer Nabi Nur</p>	 <p>Population Health Research Institute Canada</p>	<b>15</b>
<p><b>ASPIRE- AF</b></p> <p>To assess the feasibility of a randomized controlled trial of non-vitamin K oral anticoagulants versus usual care in patients with perioperative atrial fibrillation (AF) after noncardiac surgery and additional stroke risk factors.</p>	 <p>Dr. Saeedullah Shah</p>	 <p>Population Health Research Institute Canada</p>	<b>08</b>
<p><b>AI- SAROSH</b></p> <p>AI-based risk predictive tool for early diagnosis and treatment of Gestational Diabetes in collaboration with a team of experts specialized in AI and software development from NUST</p>	 <p>Dr. Shahnaz Nawaz</p>	 <p>PHC Global Pakistan</p>	<b>4278</b>
<p><b>WHO SURVEY</b></p> <p>Estimating and monitoring the mortality from cirrhosis and hepatocellular carcinoma attributable to viral hepatitis B and C at a national level</p>	 <p>Dr. M. Salih</p>	 <p>World Health Organization</p>	<b>2000</b>

## TRIALS

## PRINCIPAL INVESTIGATORS

## SPONSORS

## TOTAL RECRUITEMENT

### TRIALS IN FOLLOWUP PHASE

#### **BCD-178/PERJETA**

A Double-Blind, randomized clinical study of the efficacy and safety of BCD-178 and Perjeta® as Neoadjuvant therapy of HER2-Positive Breast Cancer.



Dr. Azhar Shafi



Biocad, Russia

**01**

### CONCLUDED TRIALS

#### **ACTIV- 2D**

A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect Of S-217622 compared with placebo in non-hospitalized participants with Covid-19.



Dr. Ejaz A Khan



National Institutes of Health, USA

**04**

#### **SEQIRUS**

To assess the feasibility of a randomized controlled trial of non-vitamin K oral anticoagulants versus usual care in patients with perioperative atrial fibrillation (AF) after noncardiac surgery and additional stroke risk factors.



Dr. Ejaz A Khan



Novartis, United Kingdom

**60**

#### **ALVOEYE**

A randomized, double-masked, parallel-group, multicenter, therapeutic equivalence study evaluating the efficacy, safety, and immunogenicity of AVT06 compared with Eylea in subjects with neovascular (wet) AMD.



Dr. Amer Awan



Population Health Research Institute Canada

**01**


# TRIALS IN PIPELINE

TRIALS	PRINCIPAL INVESTIGATOR	SPONSOR
<p><b>LIMIT</b></p> <p>To assess the feasibility of a large trial to evaluate the safety and efficacy of a common, lower INR target range in patients with bileaflet aortic mechanical valves.</p>	 <p>Dr. M Afsheen Iqbal</p>	 <p>Population Health Research Institute Canada</p>
<p><b>THE SHIPPS STUDY</b></p> <p>A multi-institutional, prospective, controlled, randomized, double-blinded interventional trial to examine the potential benefits and risks of adjunctive hydrocortisone in Paediatric Septic shock.</p>	 <p>Dr. Ejaz A Khan</p>	 <p>Canadian Institute of Health Research</p>
<p><b>RADIO TB</b></p> <p>RADIO-TB trial - Optimal treatment of Radiographically Apparent, Bacteriologically Negative Tuberculosis</p>	 <p>Dr. Syed Murtaza Kazmi</p>	 <p>Wellcome Trust</p>
<p><b>BENITO</b></p> <p>Randomized, Multicenter, Multinational, Double-Blind Study to Compare the Pharmacokinetics, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) versus Keytruda® in Combination with Chemotherapy for the Treatment of Patients with Advanced Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)</p>	 <p>Dr. Muhammad Farrukh</p>	 <p>MabXience</p>


# INVESTIGATOR INITIATED PROTOCOLS AT SIH 2024

## IRB RESEARCH PROPOSALS


Total protocols submitted at IRB = 596



Approved




Not Approved




In process

## SELECTED PROPOSALS BY INSTITUTIONS (SIH AND AFFILIATES)




# SHIFA CANCER REGISTRY

Shifa Cancer Registry is a hospital based registry developed in 2018 for collecting accurate and complete data of patients diagnosed and/or treated for cancer at the hospital.




## Shifa Oncology Center total patients visit 2013-2023



## Cancer Registry Data


The registry recorded a 63.8% increase in cases from 2018 to 2022



## Data Requests

Trial Data Requests

IRB Data Requests




7




6

## New Initiatives in 2024


Cancer Registry Data Sharing Form




Cancer Registry Data Sharing Policy



Implementation of a Role Management System




# STATISTICAL FACILITATION



## PG TRAINEES RESEARCH COURSE

*Delivering research training sessions to postgraduate trainees*

**130**



## STATISTICAL FACILITATION

*Delivering detailed statistical insights for informed decision-making and providing precise calculations to optimize research design*

**443**



## PROTOCOL APPRAISALS

*Scrutinizing research protocols to confirm they align with quality standards*

**65**

# CAPACITY BUILDING


**Post-Graduate Medical  
Education (PGME) Sessions**

**Associate of Science in Medical  
Technology (ASMT) Lectures**


**Clinical Research Course  
for Pharmacy Students**

# PUBLICATION TREND OVER THE YEARS

*Rising Impact, Year After Year*



## FEASIBILITY STUDIES IN 2024



# SCRC PUBLICATIONS 2024

**JCPSP** OPEN ACCESS  
Journal of the College of Physicians and Surgeons Pakistan  
ISSN: 1022-386X (PRINT)  
ISSN: 1681-7168 (ONLINE)  
Volume 34, 12 Issues, 2024  
5-YEAR IMPACT FACTOR: 0.9  
-- SUBMIT YOUR MANUSCRIPT

HOME ABOUT JCPSP EDITORIAL BOARD INSTRUCTIONS FOR AUTHORS E-PUB AHEAD GUIDELINES QUALITATIVE STUDIES INDEXED IN POLICIES ARCHIVES SEARCH

ORIGINAL ARTICLE AUGUST 2024  
DOWNLOAD FULL ARTICLE

## Outcomes of Mechanical Resection of Endometrial Polyps and Submucosal Fibroids Through TruClear™ Hysteroscopy

By Shazia Fakhar<sup>1</sup>, Maria Tasneem<sup>1</sup>, Tehreem Zahid<sup>2</sup>

**AFFILIATIONS**  
1. Department of Obstetrics and Gynaecology, Shifa International Hospital, Islamabad, Pakistan  
2. Clinical Research Centre, Shifa International Hospital, Islamabad, Pakistan

doi: 10.29271/jcpsp.2024.08.885

**Cureus**  
Part of SPRINGER NATURE

Open Access Original Article

## Emerging Trends in Lung Cancer Presentation at a Leading Tertiary Oncology Center and the Need for Lung Cancer Screening in Pakistan

Syed Murtaza Hassan Kazmi<sup>1</sup>, Asif Masood<sup>2</sup>, Sumaira Gulzar<sup>3</sup>, Azhar Shafi<sup>4</sup>

1. Department of Pulmonology, Shifa International Hospital Islamabad, Islamabad, PAK 2. Department of Radiation Oncology, Shifa International Hospital Islamabad, Islamabad, PAK 3. Clinical Research Center, Shifa International Hospital Islamabad, Islamabad, PAK 4. Department of Medical Oncology, Shifa International Hospital Islamabad, Islamabad, PAK

Corresponding author: Syed Murtaza Hassan Kazmi, murtaza.kazmi@gmail.com

Review began 09/18/2024  
Review ended 09/24/2024  
Published 09/28/2024

© Copyright 2024  
Murtaza Hassan Kazmi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**KeAi**  
CHINESE ROOTS  
GLOBAL IMPACT

NeuroMarkers

journal homepage: [www.keaipublishing.com/en/journals/neuromarkers/](http://www.keaipublishing.com/en/journals/neuromarkers/)



## The role of machine learning in discovering biomarkers and predicting treatment strategies for neurodegenerative diseases: A narrative review

Abdullahi Tunde Aborode<sup>a</sup>, Ogunware Adedayo Emmanuel<sup>b</sup>, Isreal Ayobami Onifade<sup>c</sup>, Emmanuel Olotu<sup>d</sup>, Oche Joseph Otokpa<sup>e,f</sup>, Qasim Mehmood<sup>g</sup>, Suliat Iyabode Abdulai<sup>h</sup>, Abdullahi Jamiu<sup>h</sup>, Abraham Osinuga<sup>i</sup>, Christian Inya Oko<sup>j</sup>, Sodiq Fakorede<sup>k</sup>, Mustapha Mangdow<sup>l</sup>, Oloyede Babatunde<sup>l</sup>, Zainab Olapade<sup>m</sup>, Awolola Gbonjubola Victor Aboosedo Salami<sup>o</sup>, Idowu A. Usman<sup>p</sup>, Victor Ifechukwude Agboli<sup>p</sup>, Ridwan Olamilekan Ac

Arch Suicide Res. 2024 Dec 10:1-11. doi: 10.1080/13811118.2024.2438218. Online ahead of print.

## Suicide Patterns in Northern Pakistan: A 10-Year Analysis of Police Records from Three Districts of Gilgit-Baltistan

Abdul Wahab Yousafzai, Maliha Aziz, Saman Yousuf, Shakila Bano, Murad Moosa Khan

PMID: 39655452 DOI: 10.1080/13811118.2024.2438218

Access Options

**JCPSP** OPEN ACCESS  
Journal of the College of Physicians and Surgeons Pakistan  
ISSN: 1022-386X (PRINT)  
ISSN: 1681-7168 (ONLINE)  
Volume 34, 12 Issues, 2024  
5-YEAR IMPACT FACTOR: 0.9  
-- SUBMIT YOUR MANUSCRIPT

HOME ABOUT JCPSP EDITORIAL BOARD INSTRUCTIONS FOR AUTHORS E-PUB AHEAD GUIDELINES QUALITATIVE STUDIES INDEXED IN POLICIES ARCHIVES SEARCH

LETTER TO THE EDITOR SEPTEMBER 2024  
DOWNLOAD FULL ARTICLE

## Unchecked Antibiotic Access: A Looming Crisis in Pakistan

By Amna Khan, Sundus Dadan

**AFFILIATIONS**  
1. Shifa Clinical Research Centre, Shifa International Hospital, Islamabad, Pakistan

doi: 10.29271/jcpsp.2024.09.1141

**Journal of Health and Rehabilitation Research** JHRR  
2791-156X

For contributions to JHRR, contact at email: editor@jhrr.com

Original Article

## Unveiling the Spectrum of Megaloblastic Anemia: Insights from a Multifaceted Study at Abbas Institute of Medical Sciences, Muzaffarabad

Abdul Mannan Kiani<sup>1</sup>, Allah Dad Khan<sup>2</sup>, Nabeel Saeed<sup>3</sup>, Syed Sohail Ahmad<sup>4</sup>,

<sup>1</sup> Abbas Institute of Medical Sciences (AIMS)

<sup>2</sup> Institute of Health Sciences, Hazara Campus

<sup>3</sup> Comsats University Islamabad

<sup>4</sup> Khyber Pakhtunkhwa Institute of Medical Sciences, Peshawar

Epub 2024 Apr 18.

## Prevalence and knowledge of polycystic ovary syndrome (PCOS) and health-related practices among women of Syria: a cross-sectional study

Haidara Bohsas<sup>1</sup>, Hidar Alibrahim<sup>1</sup>, Sarya Swed<sup>1</sup>, Yasmeen Abouainain<sup>2</sup>, Ahmed Aljabali<sup>3</sup>, Lazaward Kazan<sup>4</sup>, Yazan Khair Eldien Jabban<sup>5</sup>, Qasim Mehmood<sup>6</sup>, Bisher Sawaf<sup>7</sup>, Nourhan Eissa<sup>5</sup>, Meriam Alkasem<sup>5</sup>, Yasmine Edrees<sup>5</sup>, Ivan Cherez-Ojeda<sup>8</sup>, Sherihan Fathey<sup>9</sup>, Gowhar Rashid<sup>10</sup>, Wael Hafez<sup>11,12</sup>, Elrashed Abdelrahim<sup>13</sup>, Hamid Osman<sup>13</sup>, Talha Bin Emran<sup>14</sup>, Refat Khan Pathan<sup>15</sup>, Maveen Uddin Khandaker<sup>16,17</sup>

# SCRC PUBLICATIONS 2024



**JCPSP** OPEN ACCESS  
Journal of the College of Physicians and Surgeons Pakistan  
ISSN: 1022-385X (PRINT)  
ISSN: 1687-7168 (ONLINE)  
-- SUBMIT YOUR MANUSCRIPT  
5-YEAR IMPACT FACTOR: 0.9  
Volume 34, 12 Issues, 2024

HOME ABOUT JCPSP EDITORIAL BOARD INSTRUCTIONS FOR AUTHORS E-PUB AHEAD GUIDELINES QUALITATIVE STUDIES INDEXED IN POLICIES ARCHIVES SEARCH

LETTER TO THE EDITOR MARCH 2024 DOWNLOAD FULL ARTICLE

### The Potential of Immature Platelet Fraction as a Prognostic Marker in Dengue Infection

By Amna Khan, Tehreem Zahid

**AFFILIATIONS**  
1. Clinical Research Centre, Shifa International Hospital, Islamabad, Pakistan

doi: 10.29271/jcpsp.2024.03.374

## Evaluation of acute stroke care services in Sindh, Pakistan: a situational analysis



**Abdul Malik**  
Department of Neurology, Liaquat College of Medicine & Dentistry, Karachi, Pakistan

**Muhammad Athar Khan**  
Department of Community Medicine, Liaquat College of Medicine & Dentistry, Karachi, Pakistan

**Maimoona Siddiqui**  
Department of Neurology, Shifa International Hospital, Shifa Tameer-i-

> J Public Health (Oxf). 2024 Aug 25;46(3):e439-e447. doi: 10.1093/pubmed/fdae111.

## Female education ban by the Taliban: A descriptive survey study on suicidal ideation, mental health, and health-related quality of life among girls in Afghanistan



Abdul Qadim Mohammadi<sup>1</sup>, Ahmad Neyazi<sup>2</sup>, Diva Habibi<sup>2</sup>, Qasim Mehmood<sup>3</sup>, Mehrab Neyazi<sup>2</sup>, Mark D Griffiths<sup>4</sup>

Affiliations + expand

PMID: 38936836 DOI: 10.1093/pubmed/fdae111

> Front Pharmacol. 2024 Sep 4;15:1441251. doi: 10.3389/fphar.2024.1441251. eCollection 2024.

## Association of *SLCO1B1* gene variants with angiotensin-converting enzyme inhibitor-induced cough in a Pakistani hypertensive cohort



Arooj Fatima Sheikh<sup>1</sup>, Nayla Munawar<sup>2</sup>, Rukhsana Nawaz<sup>3</sup>, Hizbullah Khan<sup>4,5</sup>, Mehwish Rafique<sup>6</sup>, Faryal Jahan<sup>1</sup>, Sagheer Ahmed<sup>1</sup>

Affiliations + expand

> Discov Ment Health. 2024 Sep 20;4(1):38. doi: 10.1007/s44192-024-00090-5.

## Health survey on anxiety, depression, and stress in Afghanistan: A large-scale cross-sectional study amid ongoing challenges



Ahmad Neyazi<sup>1,2</sup>, Abdul Qadim Mohammadi<sup>3</sup>, Nosaibah Razaqi<sup>4</sup>, Bilal Ahmad Rahimi<sup>5</sup>, Sifatullah Sifat<sup>6</sup>, Najeebullah Rahimi<sup>7</sup>, Zarghoon Tareen<sup>5</sup>, Qasim Mehmood<sup>8</sup>, Prakasini Satapathy<sup>9</sup>, Mark D Griffiths<sup>10</sup>

Affiliations + expand

PMID: 39302527 PMCID: PMC11415558 DOI: 10.1007/s44192-024-00090-5

> J Public Health Res. 2024 Oct 24;13(4):22799036241294172. doi: 10.1177/22799036241294172. eCollection 2024 Oct.

## Elder abuse in the transgender community of Pakistan: A clandestine issue



Aleena Mujahid<sup>1</sup>, Fatima Rajab<sup>1</sup>, Muhammad Subtain Kazim<sup>1</sup>, Qasim Mehmood<sup>1</sup>

Affiliations + expand

PMID: 39493702 PMCID: PMC11528612 DOI: 10.1177/22799036241294172

# HIGHLIGHTS OF THE YEAR



A special mention of SCRC team in the newsletter and praise from Dr. David Conen, Principal Investigator from Canada



Meeting with PJ Devereaux, principal scientist at PHRI, Canada at SIHL to discuss the HIP-ATTACK2 and ASPIRE-AF trials.



Participation of SCRC team in an expert consultation organized by the World Health Organization (WHO), NHSRC, and DRAP.



SCRC team at 17th ANRD with Dr. Fahad being the organizer and Dr. Qasim being the moderator



Meeting with Dr. Timo Tolppa, a UK-based global health researcher and coordinator of PPIE



SCRC team at Joint Commission International (JCI) reaccreditation survey



Meeting with NUST & PHC Global to review AI SAROSH progress and explore future collaboration.



SCRC team at the Symposium on Future of Clinical Trials in Pakistan at Rehman Medical Institute (RMI), Peshawar



Poster presentation by Dr. Sabhat and Dr. Sofia at the 14th International Public Health Conference, HSA, Islamabad.



Mr. Abdul Manan Kiani won 3rd prize in the 17th ANRD poster competition.



Certificate Distribution for the first Pharmacy Residents' Research Course



Meeting of SCRC team for process improvements and workflow development

- Integration of AI in Clinical Research
- Initiation of Phase II, bioequivalence, and medical device clinical trials
- Development of a comprehensive database of SIH physicians' research profiles
- Implementation of a remote work initiative for effective utilization of resources

2025

- Development of the SIH Publication Database
- Digitization of all study documents and patient records into E-binders
- Conducting internal audits for ongoing and closed trials
- Development of workflows designed to enhance process improvement

2024

# SCRC ROADMAP

- Expansion of the Core Team
- Establishment of State-of-the-Art Research Clinic and Clinical Trial Repository
- Diversification of the Clinical Trial Portfolio
- Digitalization of the Cancer Registry

2023



**Shifa**  
International  
Hospitals Ltd.



## Contact Us:

Shifa Clinical Research Center

Shifa International Hospitals Ltd., Islamabad

[scrc@shifa.com.pk](mailto:scrc@shifa.com.pk)

<https://www.shifa.com.pk/scrc-4/>